CSPCY OTC
CSPC Pharmaceutical Group Limited
1W: +7.1%
1M: +9.9%
3M: +21.7%
YTD: +17.8%
1Y: +8.3%
3Y: +91.7%
5Y: +23.5%
$5.10
+0.40 (+8.51%)
Weekly Expected Move ±9.5%
$4
$5
$5
$6
$6
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$52.0B
+17.2% ▲
5Y CAGR: +7.8%
Total Liabilities
$13.5B
+28.6% ▲
5Y CAGR: +10.3%
Shareholders Equity
$37.0B
+14.5% ▲
5Y CAGR: +6.9%
Cash & Investments
$9.9B
+19.7% ▲
5Y CAGR: -1.2%
Total Debt
$714M
+40.7% ▲
5Y CAGR: +14.8%
Net Debt
-$6.1B
+3.2% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $9.3B | $11.7B | $12.0B | $6.8B | $6.8B |
| Short-Term Investments | $1.4B | $4.8B | $1.1B | $1.5B | $3.1B |
| Cash & ST Investments | $10.7B | $16.5B | $13.1B | $8.3B | $9.9B |
| Net Receivables | $7.1B | $7.6B | $10.8B | $9.9B | $10.6B |
| Inventory | $2.5B | $2.6B | $3.1B | $3.1B | $3.4B |
| Other Current Assets | $0 | -$2.7B | $10.4B | $362M | $595M |
| Total Current Assets | $20.3B | $24.0B | $26.7B | $21.9B | $24.8B |
| Property, Plant & Equip. | $11.7B | $11.8B | $11.6B | $13.1B | $15.0B |
| Goodwill & Intangibles | $939M | $2.1B | $2.4B | $2.8B | $3.4B |
| Long-Term Investments | $4.4B | $3.7B | $4.6B | $4.8B | $8.0B |
| Other Non-Current Assets | $514M | $53M | $820M | $1.5B | $620M |
| Total Non-Current Assets | $17.6B | $17.8B | $19.5B | $22.5B | $27.2B |
| Total Assets | $42.5B | $41.8B | $46.3B | $44.4B | $52.0B |
| — Liabilities — | |||||
| Accounts Payable | $1.6B | $2.0B | $2.8B | $2.6B | $3.3B |
| Short-Term Debt | $0 | $174M | $450M | $392M | $513M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $738M |
| Other Current Liabilities | $1.7B | $1.5B | $495M | $946M | $6.5B |
| Total Current Liabilities | $8.8B | $10.1B | $10.2B | $9.6B | $11.3B |
| Long-Term Debt | $0 | $29M | $0 | $0 | $0 |
| Other Non-Current Liab. | $250M | $271M | $57M | $408M | $627M |
| Total Non-Current Liabilities | $687M | $1.2B | $739M | $889M | $2.2B |
| Total Liabilities | $9.7B | $11.5B | $12.4B | $10.5B | $13.5B |
| — Equity — | |||||
| Common Stock | $13.3B | $10.7B | $10.9B | $11.0B | $12.3B |
| Retained Earnings | $21.1B | $20.8B | $24.0B | $23.3B | $0 |
| Accumulated OCI | -$2.6B | -$1.7B | -$1.4B | $0 | $0 |
| Total Stockholders Equity | $31.8B | $29.8B | $33.2B | $32.3B | $37.0B |
| Total Liabilities & Equity | $42.5B | $47.3B | $50.9B | $44.4B | $52.0B |
| — Key Metrics — | |||||
| Total Debt | $103M | $621M | $707M | $507M | $714M |
| Net Debt | -$9.2B | -$11.0B | -$11.3B | -$6.3B | -$6.1B |
| Total Investments | $5.9B | $8.6B | $5.7B | $6.3B | $11.1B |